Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis

Expert Review of Vaccines

Volumn 12, Issue 2, 2013, Pages 155-167

  Richardson, Charles ^a   Bargatze, Robert F ^a   Goodwin, Robert ^a   Mendelman, Paul M ^a  

^a LigoCyte Pharmaceuticals Inc   (United States)

Author keywords

calicivirus; challenge study; clinical; gastroenteritis; immunity; norovirus; vaccine; virus like particle; VLP

Indexed keywords

CARBOHYDRATE; VIRUS VACCINE;

ACUTE GASTROENTERITIS; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; CELL CULTURE; CLINICAL TRIAL; DIARRHEA; DISEASE PREDISPOSITION; DRUG FEVER; GENOTYPE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MUSCLE CRAMP; NAUSEA; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SNEEZING; VIRUS ATTACHMENT; VIRUS INFECTION; VIRUS PARTICLE; VIRUS STRAIN; VOMITING;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CALICIVIRIDAE INFECTIONS; CLINICAL TRIALS AS TOPIC; GASTROENTERITIS; HUMANS; NOROVIRUS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84874077398     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.145     Document Type: Review

References (100)

1. Patel MM, Hall AJ, Vinjé J, Parashar UD. Noroviruses: A comprehensive review. J. Clin. Virol. 44 ( 1 ), 1-8 (2009) .
2. Hall AJ, Rosenthal M, Gregoricus N et al. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004-2005. Emerging Infect. Dis. 17 ( 8 ), 1381-1388 (2011) .
3. Hall AJ. Noroviruses: the perfect human pathogens? J. Infect. Dis. 205 ( 11 ), 1622-1624 (2012) .
4. Karst SM. Pathogenesis of noroviruses, emerging RNA viruses. Viruses 2 ( 3 ), 748-781 (2010) .
5. Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 9 ( 3 ), 299-307 (2010) .
6. Atmar RL. Noroviruses-state of the art. Food Environ. Virol. 2 ( 3 ), 117-126 (2010) .
7. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nat. Rev. Microbiol. 8 ( 3 ), 231-241 (2010) .
8. Bresee JS, Widdowson MA, Monroe SS, Glass RI. Foodborne viral gastroenteritis: challenges and opportunities. Clin. Infect. Dis. 35 ( 6 ), 748-753 (2002) .
9. Scallan E, Hoekstra RM, Angulo FJ et al. Foodborne illness acquired in the United States-major pathogens. Emerging Infect. Dis. 17 ( 1 ), 7-15 (2011) .
10. Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007. Clin. Infect. Dis. 52 ( 4 ), 466-474 (2011) .
11. Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium diffi cile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin. Infect. Dis. 2 ), 216-223 (2012) .
12. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine 49 ), 7097-7104 (2012) .
13. Zahorsky J. Hyperemesis hiemis or the winter vomiting disease. Arch. Pediatr. 46, 391-395 (1929) .
14. Kapikian AZ. The discovery of the 27-nm Norwalk virus: an historic perspective. J. Infect. Dis. 181 ( Suppl. 2 ), S295-S302 (2000) .
15. Xi JN, Graham DY, Wang KN, Estes MK. Norwalk virus genome cloning and characterization. Science 250 ( 4987 ), 1580-1583 (1990) .
16. Widdowson MA, Monroe SS, Glass RI. Are noroviruses emerging? Emerging Infect. Dis. 11 ( 5 ), 735-737 (2005) .
17. van Asten L, van den Wijngaard C, van Pelt W et al. Mortality attributable to 9 common infections: signifi cant effect of infl uenza A, respiratory syncytial virus, infl uenza B, norovirus, and parainfl uenza in elderly persons. J. Infect. Dis. 206 ( 5 ), 628-639 (2012) .
18. van Asten L, Siebenga J, van den Wijngaard C et al. Unspecifi ed gastroenteritis illness and deaths in the elderly associated with norovirus epidemics. Epidemiology 22 ( 3 ), 336-343 (2011) .
19. Rondy M, Koopmans M, Rotsaert C et al. Norovirus disease associated with excess mortality and use of statins: A retrospective cohort study of an outbreak following a pilgrimage to Lourdes. Epidemiol. Infect. 139 ( 3 ), 453-463 (2011) .
20. Desai R, Hembree CD, Handel A et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: A systematic literature review. Clin. Infect. Dis. 55 ( 2 ), 189-193 (2012) .
21. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinjé J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerging Infect. Dis. 14 ( 8 ), 1224-1231 (2008) .
22. Teunis PF, Moe CL, Liu P et al. Norwalk virus: how infectious is it? J. Med. Virol. 8 ), 1468-1476 (2008) .
23. Atmar RL, Opekun AR, Gilger MA et al. Norwalk virus shedding after experimental human infection. Emerging Infect. Dis. 10 ), 1553-1557 (2008) .
24. Aoki Y, Suto A, Mizuta K, Ahiko T, Osaka K, Matsuzaki Y. Duration of norovirus excretion and the longitudinal course of viral load in norovirus-infected elderly patients. J. Hosp. Infect. 75 ( 1 ), 42-46 (2010) .
25. Siebenga JJ, Beersma MF, Vennema H, van Biezen P, Hartwig NJ, Koopmans M. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: A model for in vivo molecular evolution. J. Infect. Dis. 198 ( 7 ), 994-1001 (2008) .
26. Lopman B, Gastañaduy P, Park GW, Hall AJ, Parashar UD, Vinjé J. Environmental transmission of norovirus gastroenteritis. Curr. Opin. Virol. 2 ( 1 ), 96-102 (2012) .
27. Green KY. Caliciviridae: the noroviruses. In: Fields Virology. Knipe HP, Howley PM (Eds). Lippincott, Williams & Wilkins Publishers, PA, USA, 949-979 (2007) .
28. Glass PJ, White LJ, Ball JM, Leparc-Goffart I, Hardy ME, Estes MK. Norwalk virus open reading frame 3 encodes a minor structural protein. J. Virol. 14 ), 6581-6591 (2000) .
29. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science 286 ( 5438 ), 287-290 (1999) .
30. Zakikhany K, Allen DJ, Brown D, Iturriza-Gómara M. Molecular evolution of GII-4 norovirus strains. PLoS ONE 7 ( 7 ), e41625 (2012) .
31. Chakravarty S, Hutson AM, Estes MK, Prasad BV. Evolutionary trace residues in noroviruses: importance in receptor binding, antigenicity, virion assembly, and strain diversity. J. Virol. 79 ( 1 ), 554-568 (2005) .
32. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66 ( 11 ), 6527-6532 (1992) .
33. Tan M, Hegde RS, Jiang X. The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J. Virol. 78 ( 12 ), 6233-6242 (2004) .
34. Tan M, Jiang X. The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J. Virol. 79 ( 22 ), 14017-14030 (2005) .
35. Tan M, Jiang X. Norovirus P particle: A subviral nanoparticle for vaccine development against norovirus, rotavirus and infl uenza virus. Nanomedicine (Lond.) 6 ), 889-897 (2012) .
36. Straub TM, Höner zu Bentrup K, Orosz-Coghlan P et al. In vitro cell culture infectivity assay for human noroviruses. Emerging Infect. Dis. 13 ( 3 ), 396-403 (2007) .
37. Herbst-Kravoletz M, Hjeelm B, Lay M et al. Lack of success in culturing Noroviruses in 3-D culture systems. Presented at: 5th International Conference on Vaccines for Enteric Diseases. Malaga, Spain, 9-11 September 2009 .
38. Papfragkou E, Hewitt J, Park GW, Straub TM, Geening G, Vinje J. Challenges of culturing human norovirus in 3-D organoid cell model. Presented at: 109th General Meeting of the American Society for Microbiology. Philadelphia, PA, USA, 17-21 May 2009 .
39. Wobus CE, Karst SM, Thackray LB et al. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2 ( 12 ), e432 (2004) .
40. Lay MK, Atmar RL, Guix S et al. Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology 406 ( 1 ), 1-11 (2010) .
41. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85 ( Pt 1 ), 79-87 (2004) .
42. Rockx BH, Bogers WM, Heeney JL, van Amerongen G, Koopmans MP. Experimental norovirus infections in non-human primates. J. Med. Virol. 75 ( 2 ), 313-320 (2005) .
43. Subekti DS, Tjaniadi P, Lesmana M et al. Experimental infection of Macaca nemestrina with a Toronto Norwalk-like virus of epidemic viral gastroenteritis. J. Med. Virol. 66 ( 3 ), 400-406 (2002) .
44. Bok K, Parra GI, Mitra T et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl Acad. Sci. USA 108 ( 1 ), 325-330 (2011) .
45. Cheetham S, Souza M, Meulia T, Grimes S, Han MG, Saif LJ. Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J. Virol. 80 ( 21 ), 10372-10381 (2006) .
46. Cheetham S, Souza M, McGregor R, Meulia T, Wang Q, Saif LJ. Binding patterns of human norovirus-like particles to buccal and intestinal tissues of gnotobiotic pigs in relation to A/H histo-blood group antigen expression. J. Virol. 81 ( 7 ), 3535-3544 (2007) .
47. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classifi cation and proposed strain nomenclature. Virology 346 ( 2 ), 312-323 (2006) .
48. Dolin R, Blacklow NR, DuPont H et al. Biological properties of Norwalk agent of acute infectious nonbacterial gastroenteri-tis. Proc. Soc. Exp. Biol. Med. 140 ( 2 ), 578-583 (1972) .
49. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med. 297 ( 2 ) 86-89 (1977)
50. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J. Infect. Dis. 161 ( 1 ) 21 (1990) .
51. Wyatt RG, Dolin R, Blacklow NR et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J. Infect. Dis. 129 ( 6 ), 709-714 (1974) .
52. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis. 185 ( 9 ), 1335-1337 (2002) .
53. Lindesmith L, Moe C, Marionneau S et al. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9 ( 5 ), 548-553 (2003) .
54. Marionneau S, Ruvoën N, Le Moullac-Vaidye B et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 122 ( 7 ), 1967-1977 (2002) .
55. Thorven M, Grahn A, Hedlund KO et al. A homozygous nonsense mutation (428G->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J. Virol. 24 ), 15351-15355 (2005) .
56. Reeck A, Kavanagh O, Estes MK et al. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 202 ( 8 ), 1212-1218 (2010) .
57. Atmar RL, Bernstein DI, Harro CD et al. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365 ( 23 ), 2178-2187 (2011) .
58. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J. Virol. 79 ( 5 ), 2900-2909 (2005) .
59. Shirato H, Ogawa S, Ito H et al. Noroviruses distinguish between type 1 and type
60. histo-blood group antigens for binding. J. Virol. 82 ( 21 ), 10756-10767 (2008) .
61. Nordgren J, Kindberg E, Lindgren PE, Matussek A, Svensson L. Norovirus gastroenteritis outbreak with a secretorindependent susceptibility pattern, Sweden. Emerging Infect. Dis. 16 ( 1 ), 81-87 (2010) .
62. Takanashi S, Wang Q, Chen N et al. Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J. Clin. Microbiol. 49 ( 9 ), 3234-3244 (2011) .
63. Tan M, Jiang X. Norovirus-host interaction: multi-selections by human histoblood group antigens. Trends Microbiol. 8 ), 382-388 (2011) .
64. Huang P, Farkas T, Zhong W et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specifi cities and classifi cation of two major binding groups among multiple binding patterns. J. Virol. 79 ( 11 ), 6714-6722 (2005) .
65. Tan M, Xia M, Chen Y et al. Conservation of carbohydrate binding interfaces-evidence of human HBGA selection in norovirus evolution. PLoS One 4 ( 4 ) e5058 (2009) .
66. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N. Engl. J. Med. 361 ( 18 ), 1776-1785 (2009) .
67. Siebenga JJ, Vennema H, Renckens B et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 18 ), 9932-9941 (2007) .
68. Lindesmith LC, Donaldson EF, Lobue AD et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5 ( 2 ), e31 (2008) .
69. Cannon JL, Lindesmith LC, Donaldson EF, Saxe L, Baric RS, Vinjé J. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J. Virol. 83 ( 11 ), 5363-5374 (2009) .
70. Yang Y, Xia M, Tan M et al. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J. Virol. 84 ( 18 ), 9595-9607 (2010) .
71. Lindesmith LC, Beltramello M, Donaldson EF et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 8 ( 5 ), e1002705 (2012) .
72. Otto PH, Clarke IN, Lambden PR, Salim O, Reetz J, Liebler-Tenorio EM. Infection of calves with bovine norovirus GIII.1 strain Jena virus: an experimental model to study the pathogenesis of norovirus infection. J. Virol. 85 ( 22 ), 12013-12021 (2011) .
73. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol. Chem. 389 ( 5 ), 521-536 (2008) .
74. Xia M, Farkas T, Jiang X. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J. Med. Virol. 79 ( 1 ), 74-83 (2007) .
75. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl Acad. Sci. USA 93 ( 11 ), 5335-5340 (1996) .
76. Santi L, Batchelor L, Huang Z et al. An effi cient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26 ( 15 ), 1846-1854 (2008) .
77. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J. Biol. Chem. 281 ( 28 ), 19478-19488 (2006) .
78. Huhti L, Blazevic V, Nurminen K, Koho T, Hytönen VP, Vesikari T. A comparison of methods for purifi cation and concentration of norovirus GII-4 capsid virus-like particles. Arch. Virol. 155 ( 11 ), 1855-1858 (2010) .
79. Kissmann J, Ausar SF, Foubert TR et al. Physical stabilization of Norwalk virus-like particles. J. Pharm. Sci. 97 ( 10 ), 4208-4218 (2008) .
80. Taylor RM. Production and downstream processing of norovirus virus-like particles. Presented at: 12th International Meeting, Baculovirus and Insect Cell Culture. San Antonio, TX, USA, 2-4 February 2009 .
81. Koho T, Mäntylä T, Laurinmäki P et al. Purifi cation of norovirus-like particles (VLPs) by ion exchange chromatography. J. Virol. Methods 181 ( 1 ), 6-11 (2012) .
82. Lai H, Chen Q. Bioprocessing of plantderived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations. Plant Cell Rep. 31 ( 3 ), 573-584 (2012) .
83. Taylor RM. Production of Norovirus virus-like particles in the baculovirus expression system from benchtop to GMP manufacturing. Presented at: ISBioTech. Rosslyn, VA, USA, 2-4 April 2012 .
84. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72 ( 2 ), 1345-1353 (1998) .
85. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75 ( 20 ), 9713-9722 (2001) .
86. Periwal SB, Kourie KR, Ramachandaran N et al. A modifi ed cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine. Vaccine 21 ( 5-6 ), 376-385 (2003) .
87. Nicollier-Jamot B, Ogier A, Piroth L, Pothier P, Kohli E. Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in BALB/c mice induce specifi c humoral and cellular Th1/Th2-like immune responses. Vaccine 22 ( 9-10 ), 1079-1086 (2004) .
88. Souza M, Costantini V, Azevedo MS, Saif LJ. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 25 ( 50 ), 8448-8459 (2007) .
89. Steadman B, Hinchcliffe M, Tino WT, Wimer SK, Sublett R, Richardson C. Product development and clinical plan for a mucosally-delivered Norwalk vaccine. Presented at: VED 2007 Vaccines for Enteric Diseases. Lisbon, Portugal, 25-27 April 2007 .
90. Parra GI, Bok K, Taylor R et al. Immunogenicity and specifi city of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30 ( 24 ), 3580-3586 (2012) .
91. LoBue AD, Lindesmith L, Yount B et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24 ), 5220-5234 (2006) .
92. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J. Virol. 83 ( 7 ), 3212-3227 (2009) .
93. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology 117 ( 1 ), 40-48 (1999) .
94. Gray JJ, Cunliffe C, Ball J, Graham DY, Desselberger U, Estes MK. Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specifi c antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus. J. Clin. Microbiol. 32 ( 12 ), 3059-3063 (1994) .
95. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108 ( 3 ), 241-247 (2003) .
96. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182 ( 1 ), 302-305 (2000) .
97. El-Kamary SS, Pasetti MF, Mendelman PM et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202 ( 11 ), 1649-1658 (2010) .
98. Ramirez K, Wahid R, Richardson C et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specifi c B memory responses in human adult volunteers. Clin. Immunol. 144 ( 2 ), 98-108 (2012) .
99. Frey SE, Treanor JJ, Atmar RL et al. Dose escalation trial of the safety and immunogenicity of a bivalent Norovirus virus-like particle vaccine administered by the intramuscular route. Presented at: 49th Annual Meeting of the Infectious Disease Society of America (IDSA). Boston, MA, USA, 20-23 October 2011 .
100. Treanor JJ, Frey S, Gormley R et al. Safety and immunogenicity of an intramuscular Norovirus VLP vaccine. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 9-12 September 2012 .